Clin2
NCT06484777Possibly a fitRecruiting

Study of SHR-9539 for multiple myeloma

Multiple Myeloma

Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.

This trial tests a new drug called SHR-9539 for people with multiple myeloma, a type of blood cancer. The goal is to see if it is safe and how it affects the cancer.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1
Enrollment
138 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You are 18 years or older.
  • You are well enough to be up and about (ECOG score 0 or 1).
  • You have been diagnosed with multiple myeloma.
  • Your doctor thinks you are likely to live at least 3 more months.
  • If you or your partner could become pregnant, you agree to use effective birth control for 3 months after the last dose.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07652281Recruiting· Phase 1
Study of SHR-5421 for multiple myeloma

This trial tests a new drug, SHR-5421, for people with multiple myeloma that has come back or stopped responding to treatment. It aims to see if the drug is safe and how well it works.

Beijing, Beijing Municipality
NCT07490613Recruiting· Phase 1
Study of SHR-3836 for people with multiple myeloma

This trial tests a new drug called SHR-3836 for patients with multiple myeloma that has come back or stopped responding to treatment. The goal is to see if the drug is safe and how it works against the cancer.

Suzhou, Jiangsu
NCT07333261Recruiting· Phase 1
Study of BMS-986453 for newly diagnosed multiple myeloma

This trial tests a new drug, BMS-986453, for people newly diagnosed with multiple myeloma. It aims to see if the drug is safe and works well for those who cannot or choose not to have a stem cell transplant.

Birmingham, Alabama
NCT07266441Recruiting· Phase 2
Study of a new drug for relapsed or refractory multiple myeloma

This trial tests an experimental drug called JNJ-79635322 for people with multiple myeloma that has come back or hasn't responded to at least three previous treatments, including a PI, an IMiD, and a CD38-targeted antibody. The goal is to see if this new drug can help control the disease.

Birmingham, Alabama
NCT07179679Recruiting· Phase 1
Study of a new shot for multiple myeloma

This trial tests a new injectable treatment for people with multiple myeloma that has come back or not responded to previous therapies. It aims to see if the drug is safe and effective.

Chongqing, Chongqing Municipality
NCT05583617Recruiting· Phase 1/Phase 2
Testing multiple treatments for multiple myeloma after prior therapy

This early-phase study tests how safe and effective several treatment approaches are for people with multiple myeloma who have already had other treatments. Depending on your myeloma features and prior care, a study drug combination may be offered to try to control the disease.

Randwick, New South Wales

Hear when a new Multiple myeloma trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.